Tiotropium 18 μg: Clinical Trials

5 trials of Tiotropium 18 μg, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 4 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 34Completed 4
Phase 11Completed 1

Follow Tiotropium 18 μg: new trials by email Literature Review of Tiotropium 18 μg trials Research Report on Tiotropium 18 μg

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD
LAS190792 Dose 1, LAS190792 Dose 2, LAS190792 Dose 3 - Chronic Obstructive Pulmonary Disease (COPD), Asthma
Phase 1CompletedAstraZeneca552013-09-012019-06-21
Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity
Indacaterol 150 μg, Tiotropium 18 μg, Placebo - Chronic Obstructive Pulmonary Disease
Phase 3CompletedNovartis Pharmaceuticals542009-10-012016-02-17
A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol - Chronic Obstructive Pulmonary Disease
Phase 3CompletedNovartis Pharmaceuticals15982009-06-012011-08-19
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol - Chronic Obstructive Pulmonary Disease (COPD)
Phase 3CompletedNovartis Pharmaceuticals11422009-04-012011-08-25
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol - Chronic Obstructive Pulmonary Disease (COPD)
Phase 3CompletedNovartis Pharmaceuticals11342009-03-012011-08-18

Conditions studied

Pulmonary Disease, Chronic Obstructive (5)  ·  Asthma (1)

Sponsors

Novartis Pharmaceuticals (4)  ·  AstraZeneca (1)

Countries

Colombia (3)  ·  Spain (3)  ·  United States (3)  ·  Canada (2)  ·  Denmark (2)  ·  Germany (2)  ·  Hungary (2)  ·  Italy (2)  ·  Mexico (2)  ·  Slovakia (2)  ·  Turkey (Türkiye) (2)  ·  United Kingdom (2)  ·  Argentina (1)  ·  Australia (1)  ·  Austria (1)

Results publications

PMID 22544891, PMID 21622587, PMID 22035851

NIH funding

2009 (1)